Coenzyme Q10 Supplementation and Heart Failure
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the Western world. Oxidative stress appears to play a pivotal role in atherosclerosis. Coenzyme Q10 (CoQ10), one of the most important antioxidants, is synthesized de novo by every cell in the body. Its biosynthesis decreases with age and its deficit in tissues is associated with degenerative changes of aging, thus implicating a possible therapeutic role of CoQl0 in human diseases. There is evidence to support the therapeutic value of CoQ10 as an adjunct to standard medical therapy in congestive heart failure. However, much further research is required, especially in the use of state-of-the-art techniques to assess functional outcomes in patients with congestive heart failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ghirlanda, G., Oradei, A., Manto, A., Lippa, S., Uccioli, L., Caputo, S., Greco, A. V., & Littarru, G. P. (1993) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1993.tb03948.x · Cited by 324
DE PINIEUX, G., CHARIOT, P., AMMI‐SAÏD, M., LOUARN, F., LEJONC, J. L., ASTIER, A., JACOTOT, B., & GHERARDI, R. (1996) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1996.04178.x · Cited by 262
Laaksonen, R., Jokelainen, K., Laakso, J., Sahi, T., Härkönen, M., Tikkanen, M. J., & Himberg, J.-J. (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)89180-1 · Cited by 171
Langsjoen, P. H., & Langsjoen, A. M. (2003) · BioFactors · doi:10.1002/biof.5520180212 · Cited by 112
Hargreaves, I. P., Duncan, A. J., Heales, S. J. R., & Land, J. M. (2005) · Drug Safety · doi:10.2165/00002018-200528080-00002 · Cited by 91
Interactions between ubiquinones and vitamins in membranes and cells
Constantinescu, A., Maguire, J. J., & Packer, L. (1994) · Molecular Aspects of Medicine · doi:10.1016/0098-2997(94)90013-2 · Cited by 73
Research works printed but not linked: 48
- Beyer, 1985, Tissue coenzyme Q (ubiquinone) and protein concentrations over the life span of the laboratory rat, Mech Ageing Dev, 32, 267, 10.1016/0047-6374(85)90085-5 · DOI
- Kalen, 1987, Ubiquinone biosynthesis by the microsomal fraction from rat liver, Biochim Biophys Acta, 926, 70, 10.1016/0304-4165(87)90183-8 · DOI · Paper page
- Bhagavan, 2006, Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinet-ics, Free Radic Res, 40, 445, 10.1080/10715760600617843 · DOI · Paper page
- Villalba, 1995, Coenzyme Q reductase from liver plasma membrane: purification and role in trans-plasma-membrane electron transport, Proc Natl Acad Sci U S A, 92, 4887, 10.1073/pnas.92.11.4887 · DOI · Paper page
- Alleva, 1995, The roles of coenzyme Q10 and vitamin E on the peroxidation of human low density lipoprotein subfractions, Proc Natl Acad Sci U S A, 92, 9388, 10.1073/pnas.92.20.9388 · DOI · Paper page
- Johansen, 1991, Coenzyme Q10, alpha-tocopherol and free cholesterol in HDL and LDL fractions, Ann Med, 23, 649, 10.3109/07853899109148098 · DOI · Paper page
- Aberg, 1992, Distribution and redox state of ubiquinones in rat and human tissues, Arch Biochem Biophys, 295, 230, 10.1016/0003-9861(92)90511-T · DOI · Paper page
- Littarru, 1972, Deficiency of coenzyme Q 10 in a succinate-CoQ Enzyme in the dystrophic rabbit on an antioxidant deficient diet, Int J Vitam Nutr Res, 42, 127
- Folkers, 1972, Survey and new clinical studies on conenzyme Q in human muscular dystrophy, Int J Vitam Nutr Res, 42, 139
- Folkers, 1985, Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10, Proc Natl Acad Sci U S A, 82, 901, 10.1073/pnas.82.3.901 · DOI · Paper page
- Lagendijk, 1997, Ubiquinol/ubiquinone ratio as marker of oxidative stress in coronary artery disease, Res Commun Mol Pathol Pharmacol, 95, 11
- Kontush, 1997, Plasma ubiquinol-10 is decreased in patients with hyperlipidaemia, Atherosclerosis, 129, 119, 10.1016/S0021-9150(96)06021-2 · DOI
- Hanaki, 1991, Ratio of low-density lipoprotein cholesterol to ubiquinone as a coronary risk factor, N Engl J Med, 325, 814, 10.1056/NEJM199109123251116 · DOI
- Hasegawa, 2005, Daily profile of plasma %CoQ10 level, a biomarker of oxidative stress in patients with diabetes manifesting postprandial hyperglycaemia, Acta Diabetol, 42, 179, 10.1007/s00592-005-0199-6 · DOI
- Lim, 2006, Oxidative burden in prediabetic and diabetic individuals: evidence from plasmacoenzyme Q(10), Diabet Med., 23, 1344, 10.1111/j.1464-5491.2006.01996.x · DOI
- Rosenfeldt, 2003, Systematic review of effect of coenzyme Q10 in physical exercise, hypertension and heart failure, Biofactors, 18, 91, 10.1002/biof.5520180211 · DOI · Paper page
- Greenberg, 1990, Co-enzyme Q10: a new drug for cardiovascular disease, J Clin Pharmacol, 30, 596, 10.1002/j.1552-4604.1990.tb01862.x · DOI · Paper page
- Yamamura, 1967, Clinical use of coenzyme Q10 for the treatment of cardiovascular disease, Jpn Circ Jl, 31, 168
- Langsjoen, 1985, Effective treatment with coenzyme Q10 of patients with chronic myocardial disease, Drugs Exp Clin Res, 11, 577
- Langsjoen, 1997, Treatment of hypertrophic cardiomyopathy with co-enzyme Q10, Mol Aspects Med, 18, S145, 10.1016/S0098-2997(97)00006-X · doi:10.1016/s0098-2997(97)00006-x
- Langsjoen, 1999, Overview of the use of CoQ10 in cardiovascular disease, Biofactors, 9, 273, 10.1002/biof.5520090224 · DOI · Paper page
- Soja, 1997, Treatment of congestive heart failure with coenzyme Q10 illuminated by meta-analyses of clinical trials, Mol Aspects Med, 18, 159, 10.1016/S0098-2997(97)00042-3 · DOI
- Sander, 2006, The impact of coenzyme Q10 on systolic function in patients with chronic heart failure, J Card Fail, 12, 464, 10.1016/j.cardfail.2006.03.007 · DOI · Paper page
- Morisco, 1993, Effect of co-enzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study, Clin Investig, 71, 134
- Rengo, 1993, Role of metabolic therapy in cardiovascular disease, Clin Inves-tig, 71, 124
- Witte, 2005, The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure, Eur Heart J, 26, 2238, 10.1093/eurheartj/ehi442 · DOI · Paper page
- Jeejeebhoy, 2002, Nutritional supplementation with MyoVive repletes essential cardiac myocytes nutrients and reduces left ventricular size in patients with left ventricular dysfunction, Am Heart J, 143, 1092, 10.1067/mhj.2002.121927 · DOI
- Berman, 2004, Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebocontrolled study, Clin Cardiol, 27, 295, 10.1002/clc.4960270512 · DOI · Paper page
- Schneeberger, 1986, Biomedical and Clinical Aspects of CoenzymeQ, 5, 325
- Vanfraechem, 1986, Biomedical and Clinical Aspects of CoenzymeQ, 5, 371
- Morisco, 1994, Noninvasive evaluation of cardiac hemodynamics during exercise in patients with chronic heart failure: effects of short-term coenzyme Q10 treatment, Mol Aspects Med, 15, 155, 10.1016/0098-2997(94)90025-6 · DOI
- Hofman-Bang, 1995, Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure. The Q10 Study Group, J Card Fail, 1, 101, 10.1016/1071-9164(95)90011-X · DOI · Paper page
- Munkholm, 1999, Coenzyme Q10 treatment in serious heart failure, Biofactors, 9, 285, 10.1002/biof.5520090225 · DOI · Paper page
- Zhou, 1999, Effects of coenzyme Q10 on myocardial protection during cardiac valve replacement and scavenging free radical activity in vitro, J Cardiovasc Surg, 40, 355
- Permanetter, 1992, Ubiquinone (coenzyme Q10) in the long-term treatment of idiopathic dilated cardiomyopathy, Eur Heart J, 13, 1528, 10.1093/oxfordjournals.eurheartj.a060096 · DOI · Paper page
- Watson, 1999, Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure, J Am Coll Cardiol, 33, 1549, 10.1016/S0735-1097(99)00064-9 · DOI
- Khatta, 2000, The effect of coenzyme Q10 in patients with congestive heart failure, Ann Intern Med, 132, 636, 10.7326/0003-4819-132-8-200004180-00006 · DOI · Paper page
- Singh, 2003, Effect of coenzyme Q10 on risk of atherosclerosis in patients with recent myocardial infarction, Mol Cell Biochem, 246, 75, 10.1023/A:1023408031111 · DOI
- Elshershari, 2003, Potential usefulness of coenzyme Q10 in the treatment of idiopathic dilated cardiomyopathy in children, Int J Cardiol, 88, 101, 10.1016/S0167-5273(02)00385-6 · DOI
- Bargossi, 1994, Exogenous CoQ10 supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors, Mol Aspects Med, 15, 187, 10.1016/0098-2997(94)90028-0 · DOI
- Mortensen, 1997, Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors, Mol Aspects Med, 18, 137, 10.1016/S0098-2997(97)00014-9 · DOI · Paper page
- Mabuchi, 2005, Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients, J Atheroscler Thromb, 12, 111, 10.5551/jat.12.111 · DOI · Paper page
- Bleske, 2001, The effect of pravastatin and atorvastatin on coenzyme Q10, Am Heart J, 142, E2, 10.1067/mhj.2001.116762 · DOI
- Stocker, 2006, Neither plasma coenzyme Q10 concentration, nor its decline during pravastatin therapy, is linked to recurrent cardiovascular disease events: a prospective case-control study from the LIPID study, Atherosclerosis, 187, 198, 10.1016/j.atherosclerosis.2005.09.004 · DOI
- Hughes, 2002, Coenzyme Q10 and differences in coronary heart disease risk in Asian Indians and Chinese, Free Radic Biol Med, 32, 132, 10.1016/S0891-5849(01)00783-3 · DOI
- Heck, 2000, Potential interactions between alternative therapies and warfarin, Am J Health Syst Pharm, 57, 1221, 10.1093/ajhp/57.13.1221 · DOI · Paper page
- Bonakdar, 2005, Coenzyme Q10, Am Fam Physician, 72, 1065
- Vogel, 2005, Task Force on Clinical Expert Consensus Documents (Writing Committee to Develop an Expert Consensus Document on Complementary and Integrative Medicine), J Am Coll Cardiol, 46, 184, 10.1016/j.jacc.2005.05.031 · DOI
Cited by
Mitochondrial Dysfunction and Oxidative Stress in Alzheimer’s Disease
Misrani, A., Tabassum, S., & Yang, L. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.617588 · Cited by 654
Antioxidant Therapy: Current Status and Future Prospects
Firuzi, O., Miri, R., Tavakkoli, M., & Saso, L. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711803414368 · Cited by 468
Choi, S. J., & McClements, D. J. (2020) · Food Science and Biotechnology · doi:10.1007/s10068-019-00731-4 · Cited by 298
Clinical applications of coenzyme Q₁₀
Garrido-Maraver, J. (2014) · Frontiers in Bioscience · doi:10.2741/4231 · Cited by 178
“On the other hand, since it acts like vitamin K, it may counteract the anticoagulant effects of warfarin (134).”
BackgroundLee, B.-J., Tseng, Y.-F., Yen, C.-H., & Lin, P.-T. (2013) · Nutrition Journal · doi:10.1186/1475-2891-12-142 · Cited by 170
“Coenzyme Q10 is an intracellular antioxidant that protects the membrane phospholipids, mitochondrial membrane protein, and LDLC from free radical-induced oxidative damage [12,13].”
Background
Metadata
- Authors
- Singh, U., Devaraj, S., & Jialal, I.
- Venue
- Nutrition Reviews
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-06-28
- Volume
- 65
- Issue
- 6
- Pages
- 286-293
- ISSN
- 0029-6643 (ISSN-L)
- OpenAlex
- W2124841434
- Cited by
- 103
- References
- 6
- FWCI
- 1.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Coenzyme Q10 Supplementation and Heart Failure. https://app.cochat.ai/papers/10.1111/j.1753-4887.2007.tb00306.x
- The paper
- Singh, U., Devaraj, S., & Jialal, I. (2008). Coenzyme Q10 Supplementation and Heart Failure. Nutrition Reviews. https://doi.org/10.1111/j.1753-4887.2007.tb00306.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.